Radioisotopes are used worldwide in a range of medical, industrial, research and academic applications. A large proportion of these radioisotopes are produced in particle accelerators, and the number of institutions that operate linear accelerators or cyclotrons and manufacture and distribute radiopharmaceuticals, for example, is significant and increasing. The production of radioisotopes using particle accelerators poses significant radiation hazards to workers, members of the public, and the environment when accelerators are operated without adequate radiation safety measures. This Safety Guide provides practical guidance for implementing radiation protection and safety measures in such facilities involved in the production and use of radioisotopes.

Cyclotrons are currently used for the preparation of a wide variety of radionuclides that have applications in single photon emission computed tomography (SPECT) and positron emission tomography (PET). Consequently, there is high demand from IAEA Member States for support in the area of radiopharmaceutical production using cyclotron produced radioisotopes. This publication describes the potential radionuclide production routes using cyclotrons in different energy ranges and provides methods for the development of targets and provides details of the chemistry for the separation of radionuclides from target materials. The readership of this publication includes scientists, operators interested in putting this technology into practice, technologists already working with cyclotrons who wish to enhance the utility of existing machines, and managers in the process of setting up radionuclide facilities in their countries. Students working towards higher level degrees in related fields may also benefit from this publication.

Radioactive isotopes and enriched stable isotopes are used widely in medicine, agriculture, industry, and science, where their application allows us to perform many tasks more accurately, more simply, less expensively, and more quickly than would otherwise be possible. Indeed, in many casesâ€"for example, biological tracersâ€"there is no alternative. In a stellar example of "technology transfer" that began before the term was popular, the Department of Energy (DOE) and its predecessors has supported the development and application of isotopes and their transfer to the private sector. The DOE is now at an important crossroads: Isotope production has suffered as support for DOE's laboratories has declined. In response to a DOE request, this book is an intensive examination of isotope production and availability, including the education and training of those who will be needed to sustain the flow of radioactive and stable materials from their sources to the laboratories and medical care facilities in which they are used. Chapters include an examination of enriched stable isotopes; reactor and accelerator-produced radionuclides; partnerships among industries, national laboratories, and universities; and national isotope policy.

Cyclotrons are used for preparation of a wide variety of radionuclides that find application in single photon emission computed tomography (SPECT) as well as in positron emission tomography (PET). This publication gives comprehensive guidelines for the planning and decision making processes and design and implementation of a cyclotron based radionuclide production facility. It will enable Member States to plan such facilities in a cost effective manner.

Radioisotopes are used worldwide in a range of medical, industrial, research and academic applications. A large proportion of these radioisotopes are produced in particle accelerators, and the number of institutions that operate linear accelerators or cyclotrons and manufacture and distribute radiopharmaceuticals, for example, is significant and increasing. The production of radioisotopes using particle accelerators poses significant radiation hazards to workers, members of the public, and the environment when accelerators are operated without adequate radiation safety measures. This Safety Guide provides practical guidance for implementing radiation protection and safety measures in such facilities involved in the production and use of radioisotopes.

The decay product of the medical isotope molybdenum-99 (Mo-99), technetium-99m (Tc-99m), and associated medical isotopes iodine-131 (I-131) and xenon-133 (Xe-133) are used worldwide for medical diagnostic imaging or therapy. The United States consumes about half of the world's supply of Mo-99, but there has been no domestic (i.e., U.S.-based) production of this isotope since the late 1980s. The United States imports Mo-99 for domestic use from Australia, Canada, Europe, and South Africa. Mo-99 and Tc-99m cannot be stockpiled for use because of their short half-lives. Consequently, they must be routinely produced and delivered to medical imaging centers. Almost all Mo-99 for medical use is produced by irradiating highly enriched uranium (HEU) targets in research reactors, several of which are over 50 years old and are approaching the end of their operating lives. Unanticipated and extended shutdowns of some of these old reactors have resulted in severe Mo-99 supply shortages in the United States and other countries. Some of these shortages have disrupted the delivery of medical care. Molybdenum-99 for Medical Imaging examines the production and utilization of Mo-99 and associated medical isotopes, and provides recommendations for medical use.